Acciones Immunoprecise Antibodies Ltd Other OTC
Acciones
CA87588T1030
Farmacéuticos
Ventas 2024 * | 24,59 M 17,85 M 16,54 M | Ventas 2025 * | 29,82 M 21,65 M 20,06 M | Capitalización | 35,83 M 26,01 M 24,11 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -12 M -8,71 M -8,07 M | Resultado Neto 2025 * | -9 M -6,53 M -6,05 M | VE / Ventas 2024 * | 1,46 x |
Posición de caja neta 2024 * | - 0 0 | Posición de caja neta 2025 * | - 0 0 | VE / Ventas 2025 * | 1,2 x |
P/E ratio 2024 * |
-2,82
x | P/E ratio 2025 * |
-3,82
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 86,41 % |
Último transcript sobre Immunoprecise Antibodies Ltd
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+0,82 % | 91,94 mil M | |
-1,32 % | 38,74 mil M | |
-12,88 % | 32,82 mil M | |
+64,77 % | 26,66 mil M | |
-16,31 % | 15,32 mil M | |
-5,78 % | 13,3 mil M | |
-11,38 % | 11,65 mil M | |
+173,10 % | 10,37 mil M | |
-49,84 % | 10,12 mil M |